blisibimod   Click here for help

GtoPdb Ligand ID: 9518

Synonyms: A-623 | AGP3 peptibody [5] | AMG 623 | Fc-Agp-3 [1]
Immunopharmacology Ligand
Comment: Blisibimod is a peptibody fusion containing four BAFF binding domains fused to a human Fc domain. By sequestering circulating BAFF ligand, it acts as a functional antagonist of BAFF interaction with the TACI receptor on B cells.
Peptide sequences and structural information for this peptide are available from its IMGT/mAb-DB entry. The peptide sequence for blisibimod is claimed in Amgen's patent WO2002092620 [5].
Immunopharmacology Comments
Blisibimod is a clinical candidate in the search for effective therapy for systemic lupus erythematosus (SLE) [3-4,6-7] and other autoimmune diseases. Preliminary results from the Phase 3 CHABLIS-SC1 study (NCT01395745) showed some improvement relative to placebo, but this did not reach statistical significance (results yet to be published in a peer reviewed article).
Immunopharmacology Disease
Disease X-Refs Comment References
Systemic lupus erythematosus Disease Ontology: DOID:9074
OMIM: 152700
Orphanet: ORPHA536
Blisibimod is an investigational SLE agent. 2